FBIO Fortress Biotech Inc.

1.46
-0.06  -4%
Previous Close 1.52
Open 1.51
Price To Book 4.56
Market Cap 95,236,720
Shares 65,230,630
Volume 127,463
Short Ratio
Av. Daily Volume 453,013

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated later in 2019.
CK-101
Non-small cell lung cancer (NSCLC) and other solid tumors
Phase 1 readout due 2019.
MB-101
Glioblastoma
Phase 2b/3 trial to be initiated early 2020.
CAEL‐101
AL amyloidosis
Phase 2 data in adults due 2021.
CEVA101
Severe Traumatic Brain Injury
Phase 2 data in children due 2020.
CEVA101
Severe Traumatic Brain Injury
Phase 3 trial ongoing. NDA filing due 2020.
CUTX-101
Menkes disease
Phase 3 data released June 3, 2019 met primary endpoint.
Intravenous (IV) tramadol
Postoperative pain following bunionectomy surgery
Phase 1/2 trial ongoing. Initial data noted in NEJM.
MB-107
X-linked Severe Combined Immunodeficiency (XSCID)
Phase 1 initial data due 2019.
MB-106
B-cell Non-Hodgkin Lymphoma & Chronic Lymphocytic Leukemia (CLL)
Phase 3 trial to be initiated 1H 2020.
Triplex
Cytomegalovirus (CMV)
Phase 1/2 trial to be initiated late 2019 or 2020.
MB-104
Multiple myeloma

Latest News

  1. Have Insiders Been Selling Fortress Biotech, Inc. (NASDAQ:FBIO) Shares?
  2. Checkpoint Therapeutics Added to Russell 2000® Index
  3. Avenue Therapeutics Announces Positive Topline Data from Second Pivotal Phase 3 Study of Intravenous Tramadol in the Management of Postoperative Pain
  4. Mustang Bio and St. Jude Children’s Research Hospital to Participate in Panel Discussion at Boston CEO 2019
  5. Will Fortress Biotech to Surge Higher?
  6. Mustang Bio and Nationwide Children’s Hospital Receive Orphan Drug Designation for MB-108 (Oncolytic Virus C134) for the Treatment of Malignant Glioma
  7. Mustang Bio to Present at the Cell & Gene Therapy USA Congress 2019
  8. Avenue Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights
  9. Fortress Biotech: 1Q Earnings Snapshot
  10. Fortress Biotech Reports First Quarter 2019 Financial Results and Recent Corporate Highlights
  11. Checkpoint Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights
  12. Mustang Bio Announces Full Exercise of Option
  13. Mustang Bio Announces City of Hope Opens First-of-Its-Kind Multiple Myeloma CAR T Cell Therapy Trial Targeting CS1 Protein
  14. Checkpoint Therapeutics Announces Positive Interim Clinical Results of Anti-PD-L1 Antibody Cosibelimab
  15. Avenue Therapeutics Announces Appointment of Dr. Thomas G. Moore to Board of Directors
  16. Mustang Bio Announces Proposed Public Offering of Common Stock
  17. What Kind Of Shareholders Own Fortress Biotech, Inc. (NASDAQ:FBIO)?
  18. Is Mustang Bio the Next Great Biotech Stock?
  19. St. Jude Children’s Research Hospital publishes results of Lentiviral Gene Therapy for Treatment of Infants with X-linked Severe Combined Immunodeficiency in New England Journal of Medicine